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Summary: Red blood cell ghosts containing entrapped methotrexate were injected into mice. The distribution pattern
of the drug amongst different organs was markedly different from that observed after the injection of free methotrexate.
Methotrexate is trapped inside mice and human red blood cell ghosts by application of an electric field pulse of 8 and
12 kV/cm, respectively, for 40 /us through an isotonic red blood cell suspension containing 5 mmol/1 methotrexate
between 0-4°C. The electrical field induces a permeability change of the cell membrane, which results from the di-
electric breakdown of the cell membrane, leading to an exchange of ions and macromolecules between the cell interior
and the external medium containing the drug. After resealing by raising the temperature to 37°C, the cells contained
about 5 mmol/1 methotrexate. The methotrexate-loaded ghost population, obtained from mouse or human red blood
cells, was electrically homogeneous as shown by dielectric breakdown measurements using a hydrodynamic focusing
Coulter Counter. 25 g methotrexate labelled with 22 kBq [3',5',9(n)-3H]methotrexate (specific activity 0.63 TBq/
mmol) trapped inside human or mouse ghost cells was injected into the tail vein of mice (about 20 g body weight).
Nearly all of the entrapped methotrexate accumulated in the liver, whereas in control experiments only 0.25 of the
injected dose accumulated in the liver. This carrier system can be made specific for other organs by entrapping, in
addition to the drug, small para-, ferro-, or ferrimagnetic particles of 4 to 20 nm in diameter, and by using an external
magnetic guide.
Verteilungsspektrum von in Erythrocyten eingeschlossenem Methotrexat in der Maus
Zusammenfassung: Das Verteilungsspektrum von intravenös injiziertem Methotrexat im Organismus einer Maus läßt
sich signifikant verändern, wenn Erythrocyten als Pharmakon-Trägersysteme verwendet werden. Der Einschluß von
Methotrexat in Erythrocyten erfolgt mit Hilfe einer Feldpulstechnik. Applikation eines elektrischen Feldpulses von 8
bzw. 12 kV/cm Feldstärke und 40 $ Dauer in eine gekühlte (0—4°C) isotone Erythrocytensuspension, die 5 mmol/1
Methotrexat enthält, induziert einen dielektrischen Durchbruch der Zellmembranen der Erythrocyten, der zu einer
starken Permeabilitätsänderung der Zellmembran und demzufolge zu einem Austausch der zellulären Bestandteile mit
denen der Außenlösung führt. Die ursprünglichen Permeabilitätseigenschaften der Zellmembran werden durch Erhö-
hung der Temperatur auf 37PC regeneriert. Die mit 5 mmol/1 Methotrexat beladenen Erythrocytenpopulationen von
Mäusen und Menschen wären elektrisch homogen, wie Untersuchungen mit einem hydrodynamisch fokussierenden
Coulter Counter zeigten. 25 g Methotrexat, die mit 22 kBq [3',5',9(n)-3H]Methotrexat markiert waren, wurden in
die Schwanzvene von Mäusen (etwa 20 g Körpergewicht) injiziert. Fast das-gesamte Methotrexat, das sowohl in Men-
schen- wie auch Mäuseerythrocyten eingeschlossen wurde, konnte zur Leber dirigiert werden, während in Kontroll-
versuchen nur etwa 0,25 des frei injizierten Methotrexates in diesem Organ akkumuliert wurde. Spezifität dieser
Trägersysteme für andere Organe und Gewebe kann über den simultanen Einschluß von para-, ferro- oder ferrimagne-
tischen Substanzen von 4 bis 20 lim Durchmesser und über externe magnetische Lenkung dieser „magnetischen Ery-
throcyten" erzielt werden.
Introduction administration are often required. This results in detri-
The conventional forms of drug dosage in human mental side effects and in the inability to use pharma-
therapeutics are limited in their lack of organ-specificity cological agents with short biological half-lives. These
and short duration time of delivery. High concentra- inherent problems have motivated the research and
tions of drugs together with high frequencies of drug development of drug delivery systems that meet the
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following criteria: continuous control of spatial and
temporal delivery patterns, and extended operational
delivery times. The superiority of controlled drug
release systems over conventional dosage systems lies
in the safety, i. e. less severe side effects, and in the
therapeutic effectiveness. The controlled spatial and
temporal administration of a specific drug achieved
by drug delivery systems is expected to bring about a
pronounced alteration in the pharmaceutical spectrum.
The majority of the research and development in the
field of therapeutic drug delivery systems is geared
towards the encapsulation of drugs and enzymes in
synthetic membrane capsules (1, 2). The membrane
protects the external environment from the drug and
modulates the spatial and temporal release of the drug
into the body's fluid and tissue by the permeability
of the membrane envelope. The principal difficulties
underlying the use of such drug containing synthetic
membrane capsules.remain largely unsolved. They
lie in the need for membrane systems which have
optimal properties for both the encapsulation of a
broad diversity of drugs, and the controlled release
of the drug in time and space.
Recently we (3-6) suggested the use of biomembranes
instead of synthetic membranes for drug encapsulation;
that is to load living cells, such as red blood cells and
lymphocytes, with a specific drug. Originally the idea
to encapsulate molecules inside cells was suggested
by Zimmermann (7,8, 9), Zimmermann et al. (10)
and independently bylhler et al. (11) in relation to
the treatment of enzyme deficiency diseases. The
problem of biocompatibility is easily circumvented
if the patient's own blood is used in conjunction
with therapeutically tested, commercial drugs. The
danger of toxicity, of immunological responses, and
other adverse reactions that are conceivably intro-
duced by the synthetic membrane systems are thereby
avoided.
In this study, we report the encapsulation of metho-
trexate (Amethopterin; 4-amino-N10-methylpteroyl-
glutamic acid) in red blood cells. Clinically relevant
amounts of methotrexate could be entrapped inside
the red blood cells by dielectric breakdown techniques.
Dielectric breakdown of the cell membrane occurs in
isotonic solutions in response to an externally applied
electric field pulse of high strength and short duration
(12). The subsequent haemolysis in isotonic solution
(under various conditions) leads to a broad spectrum of
homogeneous ghost populations of different drug release
characteristics (13), a prerequisite for a broad applica-
tion of this cellular carrier system in therapeutics and
diagnosis.
Efforts were made'to prepare electrically rnethotrexate-
loaded ghost cells which are directed completely to the
liver. From the standpoint of liver tumor treatment it is
desirable to preferentially accumulate drugs (or radio-
active isotopes for local radiation) in the liver. In addi-
tion, the target specificity for the liver can be relatively
easily obtained by using cells, which differ in size, de-
formability and surface charge from intact red blood
cells, in the spleen and the liver. However, as pointed
out below, modified red blood cell systems can be
directed to any other site of the body.
Methotrexate was used because of the success of this
agent in chemotherapeutic cancer treatment. Metho-
trexate is the most widely studied and clinically useful
foläte antagonist (14—18). It is a powerful inhibitor of
the enzyme dihydrofolate reductase and has similar
binding affinities for this enzyme both from normal
mammalian tissues and from neoplastic tissues (19).
Thus the selectivity of this agent against tumors depends
upon the use of a specific transport system for the ad-
ministration of the drug. The amount of methotrexate
accumulated within the cells of the tissue is dependent
on the concentration in the blood, as there is a substan-
tial body of evidence to suggest that the drug concen-
tration in the tissue attains a rapid equilibrium with
that in the blood (19, 20). The drug concentration in
the blood is controlled by its removal in the kidney and
intestine. 6 h after intravenous injection, methotrexate
is almost completely excreted from men (21), whereas
in mice the drug is eliminated after almost l h (20).
Therefore, intermittent parenteral administration of
methotrexate, which increases the plasma concentra-
tion for a short time and, in turn, the intracellular drug
concentration, is more effective than long term low
doses. The high frequency and the high levels necessary
for treatment, on the other hand, limit the application
of methotrexate because of the severe side effects ob-
served in treated patients. For these reasons metho-
trexate was used in testing the effectiveness of red blood
cells in organ-specific administration.
Materials and Methods
Human blood was collected from apparently healthy donors. The
blood was centrifuged (4000 g, 5 min), the'buffy coat leucocyte
layer was removed, the cells were washed several times and
centrifuged with the following solution I: 138.6 mmol/1 NaCl,
12.3 mmol/1 Na2HPO4, 2.7 mmol/1 NaH2PO4> pH 7.4. Mice
blood was obtained from young male and female adult mice (ca.
18-22 g). The blood was subjected to the same procedure.
Haemolysis
Electrical haemolysis of red blood cells in isotonic solutions is
described in detail by Zimmermann & Pilwat (cf. 22, 12,13). For
the sake of clarity a brief outline of the procedure is presented.
If not otherwise stated the red blood cells were suspended in a
solution containing 105 mmol/1 KC1, 20 mmol/1 NaCl; 4 mmol/1
MgCl2, 7.6 mmol/1 Na2HPO4, 2.4 mmol/1 NaH2PO4 and 10
mmol/1 glucose (solution II). The pH of the .solution was adjusted
to 7.2. The suspension density was 1:10 (packed cells to solu-
tion). An exponentially decaying electric field is applied to
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10 ml of the red blood cell suspension by discharging a capacitor
using a spark gap (22). The electric field strength was 8 and 12
kV/cm, respectively (peak value) and the pulse duration
characterized by the decay constant was about 40 MS. The
temperature of the suspension was kept at 0-4°C. Haemo-
lysis and equilibration with the external solution occurs
in about 5 min. Methotrexate and (3l,5',9(n>3HJmethotrexate
(1.9 GBq, Amersham, specific activity 0.63 TBq/mmol) can
be added either before or 1 to 2 min after electric field applica-
tion. The lysed cells were loaded with 5 mmol/1 methotrexate
which corresponds to clinically relevant drug concentrations.
Resealing of the cells was conducted at different temperatures.
In the experiments reported here the ghost ceDs were kept for
10 min between 0—4°C, after which the temperature was
raised to 37°C for 30 min (both for human and mice ghost cells).
The ghost cells were then centrifuged at 10,000 £ for 10 min
and reincubated after several washings in solution I. The con-
centration of methotrexate entrapped in the cells was on aver-
age 0.80 of that in the outer solution.
Coulter Counter measurements
The mean volume of the loaded ghost population was measured
with a hydrodynamically focusing Coulter Counter (AEG-Tele-
funken, Ulm, West-Germany). The size distributions were
measured at increasing electric field strengths in the orifice
of the Coulter Counter (orifice dimensions: 60 μτη in length
and diameter). From the apparent shift of the size distribution,
which results from the dielectric breakdown of the cell mem-
brane, once a certain threshold value of the external electric
field in the orifice has been reached (23, 24, 25), conclusions
can be drawn with regard to the homogeneity and the electrical
properties of the cell membranes of the ghost population (10).
Degradation of ghost cells in mice and determination
of blood volume
Mouse red blood cells were labelled with 99mTc by the proce-
dure described by Hedge et ai (26). 0.5 ml mouse red blood
cells and ghost cells, respectively, were incubated for 5 min
at room temperature with 3". 7 MBq 99mTc dissolved in 9 g/1
NaCl. 5 μΐ of a solution containing 10 g/1 SnCl2 was added and
the mixture allowed to stand for a further 5 min. The cells
were then centrifuged and washed twice with solution I,
being resuspended in solution I at a suspension density of
1:10. 100 μΐ of this suspension was then injected into the
tail vein of the mice. Samples were taken 10 and 30 min after
injection and the radioactivity was determined in aliquots.
The total blood volume was estimated by comparing the radio-
activity of the sample with the total amount of Tc injected
into the tail.
Preparation of samples for scintillation counting
The mice were killed at certain time intervals over 3 h period
after injection of loaded cells into the tail vein. Organ samples
were taken from lung, heart, liver, spleen, kidney, stomach,
intestine, duodenum, blood, serum, urine, and feces. All tissue
samples were freeze dried, ground, and aliquots solub ized in
Soluene 100 (Packard). Instagel (Packard) was added after
bleaching the samples with hydrogen peroxide.
The samples were counted inNa Tricarb liquid scintillation
spectrometer (Packard). The count rates were corrected for
quenching using the external standard ratio method.
Results
Haemolysis of mouse red blood cells
There are two principle procedures used to encapsulate
drugs in red blood cells. Red blood cells can be loaded
by subjecting them to osmotic stress in media of low
tonicity and ionic strength at about 0°C. Under these
conditions the cells haemolyse and the cell interior
equilibrates with the external medium. By this procedure
a drug which is added to the external medium is diffused
into the cell interior. Restoration of the tonicity of the
external medium and increasing the temperature to
37°C leads to a resealing of the membrane with the drug
trapped inside the cell. Osmotic haemolysis was used
for the entrapment of enzymes and other macromole-
cules by Zimmermann (7), by Ihler (11), by Updike
et al. (27), and by Adriaenssens et al. (28).
This procedure is limited for a broader routine clinical
application due to several reasons. For example, loading
of cells by osmotic lysis is a very time consuming pro-
cess and the transient low ionic strengths of the solution
to which the cells are exposed during haemolysis may
alter the membrane composition and integrity (29, 30).
This, in turn, leads to a decrease in the half-life of the
loaded cells due to cell degradation in the spleen and the
liver, and also limits both a long-term application or a
specific short-term application at other tissue and organ
sites (see below).
The limitations of osmotic haemolysis were overcome by
electrical haemolysis of red blood cells in isotonic solu-
tions (10, 13). Electrical haemolysis is induced by the
dielectric breakdown of the cell membrane once a
critical membrane potential is exceeded in response
to an external applied electric field pulse of μ$ duration.
The apparent critical membrane potential of the red
blood cell membrane is of the order of 0.6 to 1.0 V
(depending on the pulse length of the applied electric
field pulse (12)). These values correspond to an external,
exponentially decaying field pulse of 2 kV/cm and
40 jus duration (12, 13). The breakdown of the cell
membrane leads to a permeability change of the cell
membrane which induces a redistribution of sodium
and potassium. At supercritical field strengths several
breakdown areas are generated in the membrane, thus
the permeability of the membrane is so significantly
altered that the redistribution of sodium and potassium
is complete. As a result of this the cells swell osmotically
and subsequently haemolysis occurs. Since the genera-
tion of the critical breakdown voltage across the cell
membrane is dependent on the cell size, higher electric
field strengths are required to haemolyse the whole cell
population.
A typical set of haemolysis curves in dependence on the
external applied electric field strength is presented in
figure 1 for mouse red blood cells suspended in 9 g/1
NaCl solution (containing 4 mmol/1 Tris/HCl) and in
solution II. The degree of haemolysis was measured in the
supernatant 10 min after field application keeping the
temperature of the cell suspension throughout this whole
process, between 0 and 4°C. Haemolysis can be pre-
vented in this field range by adding increasing concen-
trations of sucrose or larger non-electrolytes to the ex-
ternal solution or by the presence of increasing con-
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Fig. 1. The effect of different composition of the external solution on the electric field strength (peak values) required for haemolysis
of mouse erythrocytes. The pulse length of the applied external field was 40 MS. For further experimental details, see Methods
and Results.
o—D 154 mmol/1 NaCl and 4 mmol/1 Tris/HCl, pH 7.2
·—· 105 mmol/1 KC1, 20 mmol/1 NaCl, 4 mmol/1 MgCl2, 7.6 mmol/1 Na2HPO4, 2.4 mmol/1 NaH2P04, and 10 mmol/1
glucose, pH 7.2 (solution II) (total phosphate concentration: 10 mmol/1)
Δ—Δ 154 mmol/I NaCl, 4 mmol/1 Tris/HCl, and 10 mmol/1 sucrose
A—A 123.2 mmol/1 NaCl, 24.6 mmol/1 Na2HPO4, and 5.4 mmol/1 NaH2PO4 (total phosphate concentration 30 mmol/1)
ο—ο 154 mmol/1 NaCl, 4 mmol/1 Tris/HCl, and 30 mmol/1 sucrose
•—· 154 mmol/1 NaCl, 4 mmol/1 Tris/HCl, and 10 mmol/1 inulin.
centration of bivalent anions or inulin in the suspension
(fig. 1). When such "protective" substances are present
in the external solution higher electric field strengths
are then required to induce electrical haemolysis. The
shift of haemolysis to higher electric field strengths
observed for mouse red blood cells in the presence of
these protective agents is similar to that previously
reported for human red blood cells (13). The reader
should consult this reference for the theoretical aspects
of the experiments reported here. It should be pointed
out that the effect of these protective substances on the
haemolysis may result from a decrease in the kinetics of
haemolysis. Some preliminary experiments support this
point of view.
Since the electrically induced permeability change of the
red blood cell membrane increases with increasing electric
field strength, the "protective" influence of these sub-
stances can therefore be adequately used to adapt the
loading process to the molecular weight of the drug or
enzyme to be trapped inside the cells without actually
requiring haemolysis.
The ghost cells lysed under the various conditions were
resealed as outlined in the "Methods". In a set of pre-
liminary experiments it was found that for directing
methotrexate completely to the liver, application of %a*
field pulse of between 8 kV/cm to 12 kV/cm to mouse
or human red blood cells suspended in solution II is
optimal. Under these conditions complete haemolysis
occurs for both human and mouse red blood cells (fig. 1)
and ghost cells are obtained which are immediately
capable of being degraded in the liver. This is also ob-
vious from table 1 where the degradation of mouse ghost
Tab. 1. Distribution of 99mTc-labeUed mouse red blood cell
ghosts and intact red blood cells in different organs
of mice. The values refer to the total amount of f c
injected and are average Values from five and two
measurements for the ghost and intact red blood cells,
respectively.
Organ
Liver
Blood
Serum
Heart
Spleen
Kidney
Lung
Duodenum
Red blood cell
ghosts
Time (min)
10 30
0.790 0.552
0.116 0.083
0.017 0.023
0.003 0.002
0.033 0.045
0.017 0.024
0.068 0.088
0.001 0.003
Intact red blood
cells
Time (min)
10 30
0.088 0.077
0.976 1.000
0.020 0.000
0.004 0.020
0.011 0.010
0.013 0.006
0.121 0.082
0.002 0.001
cells prepared under these conditions was studied in vivo
after labelling the membranes with 99mTc. It is evident
that after 10 min about 0.80 of the injected ghost cell
membranes accumulate in the liver, whereas the control
experiments using labelled intact mouse red blood cells
show no significant disappearance of radioactivity from
the blood over a longer time interval. The latter experi-
ment also allows the calculation of the blood volume of
the mice, which was, on average, found to be 72.6 ml/kg
body weight.
Homogeneity of cells loaded with methotrexate
In order to achieve controlled drug release in time and
space the cells of the ghost population loaded with the
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drug have to be homogeneous. The homogeneity of the
ghost cell population was tested by measuring the size
distribution as a function of increasing electric field
strengths in the orifice of a hydrodynamic focusing
Coulter Counter (23, 24, 25). A typical size distribution
of ghost cells from mice prepared electrically at 12 kV/
cm (see Methods) as a function of the electric field
strength in the orifice is shown in figure 2. The size
distributions are uniformly distributed over the whole
range of the field strength. Dielectric breakdown
of the cell membrane occurs beyond a critical field
strength of 2.2 kV/cm, indicated by the discontinuity
in the straight line obtained when plotting the position
of a given volume e. g. the channel number of the
mean (modal) volume versus the electric field strength
(fig. 2). The mean volume of the mouse ghost cell popu-
lation, determined from the size distribution at low
electric field strengths after calibration of the channels
with Latex particles of known mean size, was 57 μιη3
using a shape factor of 1.1 for the deformed cells in
the orifice (volume of intact mice red blood cell: 45
Mm3). The shape factor was calculated from the ratio of
the axis of intact red blood cells taken from photographs
of the cells during their passage through a modified
Coulter orifice (Pilwat & Zimmermann, unpublished
data). The shape factor is identical both for human and
mouse red blood cells. Since the shape factor of the ghost
cells cannot be determined by this equipment the value
of the shape factor for the intact red blood cells was
taken. The corresponding apparent breakdown voltage
is about 1.4 V, calculated on the basis of the integrated
Laplace equation for elliptical cells (12). For human
ghost cells the size distributions are also normally
distributed over the whole electric field range. The
mean volume in this case was 110 μπι3 and the apparent*
breakdown voltage about 1 V. The mean volume of the
ghost cells can be varied over a long range when perfor-
ming the haemolysis in solutions, in which chloride was
replaced by bivalent anions or by addition of sucrose
and inulin (see above) or by transient osmotic shock
(13). Loading of the ghost cells with drug under the
experimental conditions delineated in the Methods
Section, did not lead to any apparent alterations in the
homogeneity of the ghost cell population (fig. 3). The
size distributions of ghost cells of mice loaded with
ca. 5 mmol/1 methotrexate were uniformly distributed
at low electric field .strengths in the orifice of the
Coulter Counter. There was also no significant skew
in the size distributions in the presence of high electric
field strengths (fig. 3). The mean volume of the loaded
6000
°4000
t
2000
k V/cm: 0.48
1 2 3
Field strength IkV/cm]
50 100
Channel number
Fig. 2. Size distributions of mouse erythrocyte ghost cells measured as a function of increasing electric field strength in the orifice of
a hydrodynamicalry focusing Coulter Counter (orifice dimensions: 60 μπι in length and diameter). The height of the voltage
pulse generated by a cell during its passage through the orifice was electronically amplified and analyzed by a pulse height ana-
lyzer containing 16 X 256 channels (25). The electronic amplification was kept constant over the whole field range. At low
electric field strength, the pulse heights generated by the cells correspond to the size of the cells. The mean volume of^he
mouse ghost cells obtained after calibration of the channels with Latex particles (mean diameter 2.02 μπι) was 57 μπι . Above
2.2 kV/cm dielectric breakdown of the cell membrane occurs, indicated by an underestimation of the actual volume of the
cells, this becomes evident when plotting the channel number of a given volume versus increasing field strength (see inset).
A sharp discontinuity occurs at a given field strength depending on the size (12). In this figure this effect is demonstrated for
the "mean volume (57 μιη5). The breakdown voltage of the cell membrane which is volume-independent (24) is calculated from
the apparent underestimation of the volume to be 1.4 V (12). Note that the size distributions are uniform over the whole field
range. No skew is observed below or above the critical external field strength where breakdown occurs. Beyond the critical
external field strength required for breakdown the size distributions become coincidental. This is to be expected as the conduc-
tivity of the ghost cell interior which is identical with that of the external solution determines the resistance for the whole cell
for supercritical field strengths (25). As the current through the orifice is increased, the measured size distribution broadens
owing to an increased sensitivity of the system, a result of the fixed resolution of the Analogue to Digital Converter combined
with the increased amplifier output. The ghost cells were prepared electrically in isotonic and isoiomc solutions by subjecting
the cell suspension (1:10 packed cells to solution) to an electric field pulse of 12 kV/cm and 40 μ5 duration. Haemolysis was
conducted between 0-4°C; the resealing process of the lysed cells was carried out for 10 min between 0-4 C and for a further
30 min at 37 °C. After several washing steps (see Methods) the resealed cells were transferred to solution I in which the size
distributions of the ghost cell population were determined.
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Fig. 3. Size distributions of mouse erythrocyte ghost cells containing 5 mmol/1 entrapped methotrexate, measured as a function of in-
creasing electric field strength. The experimental conditions are identical with those described in figure 2 with the exception
that 5 mmol/1 methotrexate were added to the isotonic solution before subjecting the cell suspension to the electric field pulse
to cause haemolysis of the erythrocytes. Note that no significant skew occurs at higher electric field strengths in the orifice of the
Coulter Counter, suggesting that the entrapment of methotrexate into the resealed ghost cells does not alter the electrical homo-
geneity of the ghost cell population.
mouse ghost cells is the same as that for the unloaded
cells, namely 57 μπι3, but the breakdown voltage is
slightly different (1.5 V). Similar results were obtained
for loaded human red blood cell ghosts.
Stability of the loaded ghost cells
Figure 4 shows cumulative data from several measure-
ments concerning the leakage rate of labelled metho-
trexate from mouse and human ghost cells at different
temperatures in vitro. The ghost cells were incubated
in solution I which is used for the injection. As indicated
in figure 4, the loaded human ghost cells are stable over
a period of 4 h without any significant leakage of
methotrexate from the cells, independently of the
temperature of the suspension. On the other hand,
leakage of methotrexate from the mouse ghost cells does
occur during this time interval. The leakage rate (about
0.07/h) is identical both at low and room temperature
over a four hour period. The leakage rate is also about
0.07 in the first hour at 37°C, after which it increases.
However, this finding is of no consequence for the loaded
cells in the blood circulation, since the ghost cells are
almost competely degraded in the liver after 10 min
(see tab. 1). On the other hand, the loss of methotrexate
from the cells observed at room or low temperature
suggests that the data measured for the accumulation
of methotrexate in the liver after 10 min, when using
mouse ghost cells as the delivery system, will be under-
estimated by about 0.07.
In order to demonstrate that storage of human ghost
cells loaded with methotrexate is, in principle, possible
over several days, we studied the stability of loaded
human ghost cells suspended in aqueous citrate-glucose
buffer stored at 4°C in the refrigerator. Aqueous citrate-
1 2
Time [h]·
Fig. 4. Stability of mouse and human ghost cells loaded with
methotrexate and suspended in solution I. The experi-
ments were co'nducted at different temperatures
(o, · 0°C; a, n 20 °C, and Δ, A 37 °C). The loaded cells
were prepared by electrical haemolysis, subjecting
the cells suspended in solution II to a field pulse of
8 kV/cm; 5 mmol/1 methotrexate and [3H]methotrexate
were added to the solution before field application. The
resealed and loaded cells were incubaied in solution I at
a suspension density of 0.06. Filled symbols refer to
mouse ghost cells while the open symbols refer to
human ghost cells. The radioactivity was determined in
the ghost cell sediment of centrifuged aliquots taken from
the suspension at different times. Average values of two
different sets of experiments are presented.
glucose buffer was used successfully in storing intact
red blood cells. From figure 5 it is obvious that a leakage
of ca. 0.1/day occurs. This seems to be relatively small,
and we feel that the stability can be improved con-
siderably, when we have more information concerning
the conditions required to prolong the half-time of the
loaded ghost cells.
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Fig. 5. Storage of methotrexate loaded human ghost cells in
aqueous citrate-dextrose buffer at 4°C. The loaded cells
were prepared by electrical haemolysis (8 kV/cm and 12
kV/cm) in solution II containing 5 mmol/1 methotrexate
and 1.9 GBq l3H]methotextrae. After resealing the cells
were incubated in aqueous citrate-dextrose buffer at a
suspension density of 0.10 (packed cells to solution). At
different times, aliquots of the suspension were removed,
centrifuged and the radioactivity determined both in the
sediment (o—o) and in the supernatant (not shown).
The data points are average values of three different sets
of experiments. The leakage of methotrexate from the
ghost cells is independent of the field strength applied
for electrical haemolysis.
Distribution of methotrexate in the mouse
Both human and mouse ghost cells were loaded with
ca. 5 mmol/1 methotrexate and [3',5'9(n)-3H]metho-
trexate suspended in solution I. If not otherwise
stated, the cell suspension density was 0.06. 200 μΐ
of this suspension was injected into the tail veins of
the mice. Control experiments were conducted with
the same amount of free methotrexate and [3H]metho-
trexate dissolved in the same amount of solution. The
injection time was about 5 s and identical for both types
of drug administration. The time course of [3H]metho-
trexate was then measured in the liver (fig. 6 and 7)
over a 3 h span and in several organs, tissues and body
fluids over a l h span (tab. 2) by killing several mice
at given time intervals. As methotrexate is not metabol-
ized in mice (31) it was considered to be valid to calculate
the accumulated drug in specific organs and tissues from
the drug count per organ (or per gram tissue and body
fluid) in relation to the total amount of methotrexate
and [3H]methotrexate injected into the vein. However,
it should be noted that metabolism of methotrexate can
occur in mice after 3 h due to intestinal bacteria (32).
The control experiments revealed that the drag applied
in the normal administration form is eliminated almost
completely by the intestine and kidney within the first
two or thiee hours after injection. This is particularly
obvious in those experiments (tab. 2) where the radio-
activity pattern over the whole body of the mouse was
investigated after 10, 30, and 60 min. The drug con-
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Fig. 6. Time course of [3H]methotrexate accumulation in the
liver of mice after a single L v. injection into the tail
of the mice. Mouse red blood cells were loaded with
methotrexate by electrical haemolysis in isotonic and
iso ionic solutions containing 5 m mo 1/1 methotrexate and
[3H]methotrexate (see Methodsand Results, and fig. 3).
For injection, the methotrexate loaded ghost cells were
suspended in solution I at a suspension density of 0.05
and injected into the tail veins of mice (body weight
18-22 g). This dose corresponds to 1.1 mg metho-
trexate/kg body weight. The circles (o—o) represent
the accumulation of methotrexate in the liver over a 3 h
period. On the lefthand scale accumulation is given in
Mg/g liver weight, on the righthand scale as a fraction
of the total amount of methotrexate injected. The values
are an average of 6 measurements. In the control runs
the same amount of methotrexate and [3H]metho-
trexate dissolved in the same amount of solution was
injected into the tail veins and the time course of
methotrexate in the liver over a 3 h period was deter-
mined (a—a). Note the marked differences in the
accumulation of methotrexate in the liver, depending
on whether the drug is administered free or entrapped in
ghost cells.
Fig. 7. Methotrexate was entrapped in human erythrocyte
ghost cells by electrical haemolysis and injected into
the tail veins of mice (o—o). The time course of the
accumulation of methotrexate was followed over a
3 h period. The experimental conditions were identical
with those described in figure 6. Squares (a—a) corre-
spond to the control runs, where free methotrexate and
[*H]methotrexate was injected i.V. The values are an
average of 6 measurements.
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Tab. 2. Distribution of [3',5',9(n)-3H] methotrexate in mice, 10, 30, and 60 min following i. v. administration of a suspension contain-
ing 50 g/l methotrexate-loaded mouse ghost cells. The ghost cells were loaded with 5 mmol/1 methotrexate by electrical haemo-
lysis (8 to 12 kV/cm). The average value of methotrexate entrapped in the cells was in the range of 0.80, resulting in a dose of
1 mg methotrexate per kg body weight. For the control, the same dose of free methotrexate was administered. The values in
brackets refer to the number of experiments.
Organ
Liver
Blood
Serum
Heart
Spleen
Kidney
Lung
Duodenum
Intestine
Stomach
Bladder
Urine
Feces
Methotrexate, encapsulated
Time (min)
10
0.790 (15)
0.078 (13)
0.033 (11)
0.004 (11)
0.025(11)
0.024(11)
0.010 (11)
0.033(11)
0.025 (9)
0.012 (10)
0.011 (9)
0.000 (10)
0.003 (10)
30
0.394 (15)
0.070 (13)
0.022 (11)
0.007 (11)
0.012(11)
0.020 (10)
0.014(11)
0.049(11)
0.082 (8)
0.011 (8)
0.009 (8)
0.148 (5)
0.005 (7)
60
0.222 (15)
0.053 (11)
0.044(11)
0.013 (11)
0.012(11)
0.021 (11)
0.009 (10)
0.042(11)
0.095 (8)
0.006 (5)
0.010 (8)
0.156 (4)
0.035 (8)
Methotrexate, free
Time (min)
10
0.300 (9)
0.048 (8)
0.023 (8)
0.002 (5)
0.001 (5)
0.017 (5)
0.004 (5)
0.050 (3)
0.200 (3)
0.004 (2)
0.023 (2)
0.000 (2)
0.118 (1)
30
0.210 (9)
0.030 (7)
0.016 (8)
0.006 (4)
0.002 (4)
0.012 (4)
0.002 (4)
0.047 (3)
0.254 (3)
0.007 (2)
0.020 (2)
0.107. (2)
0.024 (1)
60
0.085 (9)
0.022 (5)
0.011 (6)
0.006(4)
0.001 (4)
0.005 (4)
0.001 (4)
0.010 (2)
0.242 (2)
0.002 (1)
0.010 (1)
0.282 (3)
0.129 (3)
centration in the liver measured 10 min after injection
is ca. 0.30 and decays exponentially with a half time of
ca. 30 min. These results are in good agreement with
those reported by Zaharko and colleagues (20, 33).
The level of [3H]methotrexate in all other organs, tissues
and fluids does not exceed 0.05 (with exception of the
feces, intestine, and urine) of the injected dose.
The distribution pattern of [3H]methotrexate is, how-
ever, markedly different when methotrexate-loaded
red blood cells are injected. 10 min after injection be-
tween 0.75 and 1.00 of the total dose is found in the
liver. The level of [3H]methotrexate measured in the
liver after 10 min following the single i. v. injection
seems to be dependent upon the volume of the ghost
cells which were used for the entrapment of the drug.
When human red blood cell ghosts (fig. 7) were used,
almost 0.90 to 1.00 of the injected dose was found in
the liver 10 min after injection, whereas with mouse
ghost cells only about 0.75 to 0.85 of the injected dose
was measured in the liver at this time. This lower accu-
mulation found for mouse ghost cells may also be
partially explained by the small leakage rate of metho-
trexate from mouse ghost cells during the time interval
between preparation and injection as mentioned above.
Another reason may be variations in the time interval
after injection at which the peak value of accumulation
in the liver occurs. This was indicated in experiments
where samples were taken between 5 and 10 min show-
ing that the peak values lie within this time interval.
The level of methotrexate in the liver decreased ex-
ponentially, showing the same time constant as ob-
served when free methotrexate is injected; the control
values were reached after 2 to 3 h. Increasing the cell
suspension density up to 0.5 does not significantly
change the distribution of methotrexate.
It is well known, that part of the methotrexate is bound
to serum proteins (31). For this reason, it can be argued
that the differences in the radioactivity pattern result
from binding of the drug to the ghost cell membrane
proteins. This conclusion seems to be supported by the
finding that ca. 0.80 of the 99mTc-labelled mouse ghost
membranes were detected in the liver after 10 min
(tab. 1). However, in vitro experiments show that
methotrexate trapped inside ghost cells is unbound
and can be almost completely released from the cells
when subjected to hypotonic stress. Under these con-
ditions, more than ca. 0.90 to 0.95 of the trapped
methotrexate was measured in the supernatant; that
means that only ca. 0.05 of the trapped drug is ad^
sorbed on the membrane surfaces.
Discussion
The results reported here demonstrate the effectiveness
of drug administration by using red blood cells as drug
delivery systems. Up to 1.0 of the injected dose could
be directed to the liver. This result can be considered
to be a considerable progress in the treatment of liver
tumours especially when comparing it with the value of
0.5 recently published by Zimmermann ScPilwat (3)
using the red blood cell carrier system. While this paper
was in preparation, Tyrell &Ryrnan (34) described some
preliminary experiments in which they studied the
entrapment of methotrexate in ghost cells prepared by
osmotic haemolysis. The concentration of methotrexate
in the external solution in which osmotic haemolysis was
conducted was only about 50 mg/1 (0.1 mmol/1). 0.035
of methotrexate was trapped inside the re sealed ghost
cells, i. e. a considerably smaller amount than that
trapped by the electrical haemolysis. On the basis of the
adsorption experiments described here we feel strongly
that the values reported by Tyrell SiRyman reflect
more adsorption on the membrane surface than real
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entrapment of the drug inside the cells. Unfortunately,
the authors present no control experiments in which the
amount of drug adsorbed on the membrane surface
was determined. The homogeneity of the methotrexate-
loaded ghost population was also not investigated by
these authors. We consider it important to prepare
homogeneous ghost preparation in order to achieve a
controlled drug release in time and space. The electrical
haemolysis method, based on the dielectric breakdown
of the cell membrane in response to an external electric
field pulse, offers the possibility both of trapping
large quantities of drugs inside the ghost cells under
isotonic conditions and of detecting any inhomogene-
ities in the ghost cell preparation by use of dielectric
breakdown measurements on the resealed ghost cells in
the modified Coulter Counter.
A further decisive advantage of the electrical method
over the osmotic one is that the permeability changes in-
duced in the membrane can be adequately matched to
the molecular weight of the drug or enzyme to be
entrapped without actually requiring haemolysis. This
has already been shown recently by trapping urease in
human red blood cells (10).
It is obvious, however, that a broader use of cells as
delivery systems for drugs and enzymes will demand
targeting of these carriers to other selected sites of
tissues and organs. Targeting of drugs to other sites than
the liver can probably achieved by using lymphocytes
or other living cells for drug entrapment. Since di-
electric breakdown is a general phenomenon occurring
in membranes of all living cells (35, 36) including
lymphocytes (unpublished data) it would appear that
the electric field pulse method presented here is the
method of choice to trap drugs in cellular envelopes.
A more promising way as we feel to direct carrier
systems to other target specificity is to use "modified"
red blood cells. A priori the target specificity of red
blood cells seems to be restricted to the spleen and
liver. The electrical haemolysis method allows in prin-
ciple the preparation of red blood cells loaded with
drug which have still haemoglobin and identical pro-
perties compared with those of the intact cells in respect
to size, surface charge, and deformability (see above).
The life-span of such cells may be much greater than
that of those ghost cells used for directing the drug
to the liver. The maximum life-span cannot, however,
exceed the life-span of the intact red blood cells in
any way. Thus, these cells will also be degraded in the
liver If they are not captured during circulation in the
blood at another selected site of the body. The diffi-
culty in providing the cells with intrinsic specificity
for other sites can be overcome by simultaneous en-
trapment of para-, ferro-, or ferrimagnetic particles,
together with the drug, in the red blood cells. Provided
that such loaded cells have a life-span of at least 30 min,
an accumulation of the cells loaded with magnetic fine
particles at any selected site of the body can be achieved
by external application of magnetic fields. External
magnetic devices capable of providing magnetic field
gradients large enough to guide magnetic catheters
have been developed in the last 15 years (37, 38). The
magnetic fields generated by these devices are also strong
enough to direct red blood cells containing magnetic
particles to the desired location in the body. Magnetic
particles of sizes of the order of 4-20 nm are available
(39) and in vivo experiments with these fine particles
byNakamura et al. (40) have shown that they can be
easily removed from the blood either by chemical agents
or by extracorporal bypass circulation systems where
the magnetic fine particles are collected with magnetic
fields. Thus, severe complications should not occur in
the body when the particles are released. The temporal
release of the drug and, in turn, of the magnetic particles
at selected sites of the body can be achieved either by
adjusting the stability of the cell membrane via the
field application by entrapping small amounts of en-
zymes which degrade the membrane (41), or by dielectric
breakdown of the cells in vivo. Such multicomponent
systems were recently shown, in a preliminary experi-
ment, to be operational in vitro.
Thus the red blood cell system undoubtedly represents
a significant step forward in the development of a new
drug delivery system, when electrical methods are
used for the entrapment. It must be stated, however,
that much effort is needed to improve the carrier
system.
Finally, it should be pointed out that several authors
have suggested an alternative carrier system for drugs,
that is the use of liposomes (42). Recently, Kimelberg
et al. (43) suggested the entrapping of methotrexate in
positively charged liposomes. These authors demon-
strated in very elegant experiments, that the distribu-
tion pattern of methotrexate in a cynologous monkey
(Macaca irus) changes markedly when methotrexate-
loaded liposomes are injected, in comparison with the
controls. At the present experimental stage it is not
possible to decide which carrier system may be more
successful, particularly for targeting drugs to any
selected site of the body.
The studies of these and other authors show that the
liposomes are tolerated after in vivo administration
arid that drugs and pharmacologically active materials
can be injected into cells in both in vitro and in vivo
situations. Kimelberg et al. also showed that the lipo-
somes are stable for 4 h in the blood circulation. On the
other hand the preparation of methotrexate entrapped
liposomes comprises numerous steps in order to obtain
homogeneous preparations, whereas the electrically
loading process of the red blood cells with drugs is a
single step preparation. More importantly the amount
of methotrexate trapped inside the ghost cells is much
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higher than the percentage of entrapment reported by
Kimelberg et al. (42) for liposomes. It should also be
pointed out that it was not possible to direct the metho-
trexate loaded liposomes completely to the liver or
spleen. Difficulties in using liposomes may also arise in
the trapping of small magnetic particles which we be-
lieve might hold considerable promise as a potential tool
for target specific drug delivery. However, a combined
system made of liposomes and cells may be the most
effective therapeutic system in the future (41).
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